From the Guidelines
Carboxy methyl maltose is not directly related to the provided evidence, which focuses on ferric carboxymaltose (FCM), a macromolecular ferric hydroxide carbohydrate complex used for intravenous iron supplementation. The provided evidence discusses the administration, efficacy, and safety of FCM in various conditions, including chronic kidney disease, pregnancy, heavy uterine bleeding, inflammatory bowel disease, and congestive heart failure 1.
Key Points
- FCM is a safe and efficacious treatment for iron deficiency, with a lower risk of cardiovascular events and hospitalizations compared to other intravenous iron formulations 1.
- The recommended administration of FCM is as a 1000 mg single infusion, diluted in 100 mL of normal saline and infused over 20-30 minutes 1.
- FCM has been associated with treatment-emergent hypophosphatemia, and its use should be avoided in patients who require repeat infusions 1.
- The most common side effects of FCM include dizziness, headache, hypertension, hypophosphatemia, injection-site reactions, and nausea 1.
Administration Guidelines
- FCM should be administered as an undiluted slow bolus injection or as an intravenous infusion, with a maximum cumulative dose of 1000 mg iron per week 1.
- Patients should be observed for adverse effects for at least 30 minutes following each intravenous injection 1.
- Iron status should be re-evaluated at 3 months after correction of iron deficiency, and further iron repletion should be provided as needed 1.
From the Research
Carboxy Methyl Maltose
- Carboxy methyl maltose is not directly mentioned in the provided studies, however, a similar compound, ferric carboxymaltose, is discussed in the study 2.
- Ferric carboxymaltose is a macromolecular ferric hydroxide carbohydrate complex, which allows for controlled delivery of iron within the cells of the reticuloendothelial system and subsequent delivery to the iron-binding proteins ferritin and transferrin.
- The study 2 shows that ferric carboxymaltose is effective in the treatment of iron-deficiency anaemia, delivering a replenishment dose of up to 1000 mg of iron during a minimum administration time of ≤15 minutes.
- Another study 3 mentions carboxy methyl cellulose, which is used in the preparation of mouth/orally dissolving tablets, but it does not provide information about carboxy methyl maltose.
- There is no direct information available about carboxy methyl maltose in the provided studies, and the available information is about similar compounds or different topics, such as loperamide 4, 5, 6.